
Ieva Ailte
@Ieva_AH
Followers
349
Following
437
Media
28
Statuses
60
Scientist. Cancer cell biology, immunology, personalized cancer treatment. Postdoc Forum at ICR-OUH. Melanoma Meet&Greet. Family, science, music, hiking, art.
Joined January 2015
RT @AUrbanucci: Urbanucci Lab is hiring! Please share and if you are interested please take contact #postdoc #job #prostatecancer
https://….
linkedin.com
Urbanucci Lab is #hiring a #postdoctoral #researcher financed by Kreftforeningen to contribute to ongoing projects involving #singlecell and #spatialbiology in #prostatecancer . The successful...
0
13
0
RT @CCITdk: Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line. ✅Free access at @natrevdrugdisc👇.(….
0
3
0
Great overview of treatment options for melanoma and new treatment modalities in trials by @HeManJespersen at Melanoma Meet & Greet meeting on December 11th. My Christmas wish is it won’t take too long until Norwegian patients can get TIL therapies as well 🙏🏻 @Oslounivsykehus
0
1
10
Want to hear oncologist Henrik Jespersen tell about melanoma-related clinical and research activities at the Norwegian Radium Hospital? Join the next Melanoma Meet&Greet 😊 @HeManJespersen @eid_robsahm #melanoma #melanom
0
1
4
Colorful and interesting presentation by Helga Bergholtz at our Institute seminar this autumn. Characterization of the tumor microenvironment by Digital Spatial Profiling to understand the progression and invasiveness of the breast cancer. @JAVELJA #breastcancer @Oslounivsykehus
0
0
2
RT @GroupKyte: 🔬 Exciting Postdoc Opportunity .🔍 Join us in advancing Machine Learning for Cancer Immunotherapy. We're looking for a talent….
0
2
0
Nordic Melanoma Meeting 2023 in Reykjavík offered a great diversity of melanoma-related topics, interesting talks and debates. Huge thanks to organizers @Hildur10016016 @berglindosk7 , Prof. Eirikur Steingrimsson, and the participants for their contributions 😊
0
0
5
Henrik Jespersen presents the upcoming metastatic melanoma study with oncolytic peptide LTX-315 starting in 2024 at Nordic Melanoma Meeting on Iceland 👏🏼. Looking forward to follow the progress!.
@HeManJespersen presents the #NeoLIPA neoadjuvant #melanoma trial using a first in class oncolytic peptide LTX-315 at #NMM2023
0
0
5
First ICR seminar for autumn semester 2023 with more than 80 people in the audience! Presentation by Alex Corthay was both educational and intriguing! @KjetilTasken @kariannefleten @Oslounivsykehus
0
0
6
Interested in melanoma? Save the date for next Melanoma Meet & Greet on October 30th at 15.00. Trude Eid Robsahm will talk about the melanoma data and research activities they have at Cancer Registry Norway. Like and help to share 💛.@eid_robsahm @kreftregisteret @KjetilTasken
0
0
3
RT @HealthTalkNorge: – Dette er en vaksineteknologi som hele verden fikk testet ut under korona-pandemien og som nå prøves ut i flere kreft….
healthtalk.no
– Dette er en vaksineteknologi som hele verden fikk testet ut under korona-pandemien og som nå prøves ut i flere kreftstudier. Vi ser nå svært gode resultater i behandlingen av melanom, forteller...
0
2
0
Are you curious about transfer of knowledge from research to innovation? Join our next Postdoc forum event at ICR in collaboration with @OsloCancer and @UiO_LifeSci.
0
1
3
Melanoma Meet & Greet one year anniversary 🎂❤️🎉. We have been growing and have organized 5 events with diverse topics. New insights, new connections, new possibilities! @eid_robsahm @KjetilTasken @kreftregisteret
0
0
5
Team Tumor Biology running for more research on prostate cancer at Holmenkollstafetten 2023 💙. 14 amazing team members managed 18 km in 1 hr 23 min 06 sec 💪🏼😁☀️. #prostatecancer @Prostatakreft
0
0
12
RT @AUrbanucci: #holmenkollstafetten with the tumor biology department at #radiumhospitalet @OusResearch #fundraising for #prostatakreftfor….
0
1
0
Grateful for Nature and authors setting focus on these issues.
No reward - no duties. 75% of respondents have reduced the hours spent on academic duties since 2020 (Nature polls). Mostly due to burnout and unwillingness to work for free. This included attending conferences, peer reviewing manuscripts and grant proposals, committees,
0
1
1